Liang-Tzung Lin

Prof. Liang-Tzung Lin

Dept. of Microbiology & Immunology, Taipei Medical University, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2015 in Seminars in Cancer Biology
Verified
Journal Article
Open access
RMRamzi Mohammad
Ramzi Mohammad
IMIrfana Muqbil
Irfana Muqbil
LLLeroy Lowe
Leroy Lowe
CYClement Yedjou
Clement Yedjou
HHHsue-Yin Hsu
Hsue-Yin Hsu
AAAsfar S. Azmi
Asfar S. Azmi
Apoptosis or programmed cell death is natural way of removing aged cells from the body. Most of the anti-cancer therapies trigger apoptosis induction and related cell death networks to eliminate malignant cells. However, in cancer, de-regulated apoptotic signaling, particularly the activation of an anti-apoptotic systems, allows cancer cells to escape this program leading to uncontrolled proliferation resulting in tumor survival, therapeutic resistance and recurrence of cancer. This resistance is a complicated phenomenon that emanates from the interactions of various molecules and signaling pathways. In this comprehensive review we discuss the various factors contributing to apoptosis resistance in cancers. The key resistance targets that are discussed include (1) Bcl-2 and Mcl-1 proteins; (2) autophagy processes; (3) necrosis and necroptosis; (4) heat shock protein signaling; (5) the proteasome pathway; (6) epigenetic mechanisms; and (7) aberrant nuclear export signaling. The shortcomings of current therapeutic modalities are highlighted and a broad spectrum strategy using approaches including (a) gossypol; (b) epigallocatechin-3-gallate; (c) UMI-77 (d) triptolide and (e) selinexor that can be used to overcome cell death resistance is presented. This review provides a roadmap for the design of successful anti-cancer strategies that overcome resistance to apoptosis for better therapeutic outcome in patients with cancer.

25 August 2011 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
RNRyan S Noyce
Ryan S Noyce
DBDaniel G Bondre
Daniel G Bondre
MHMichael Ha
Michael Ha
LLLiang-Tzung Lin
Liang-Tzung Lin
GSGary Sisson
Gary Sisson
CRChristopher Richardson
Christopher Richardson
Vaccine and laboratory adapted strains of measles virus can use CD46 as a receptor to infect many human cell lines. However, wild type isolates of measles virus cannot use CD46, and they infect activated lymphocytes, dendritic cells, and macrophages via the receptor CD150/SLAM. Wild type virus can also infect epithelial cells of the respiratory tract through an unidentified receptor. We demonstrate that wild type measles virus infects primary airway epithelial cells grown in fetal calf serum and many adenocarcinoma cell lines of the lung, breast, and colon. Transfection of non-infectable adenocarcinoma cell lines with an expression vector encoding CD150/SLAM rendered them susceptible to measles virus, indicating that they were virus replication competent, but lacked a receptor for virus attachment and entry. Microarray analysis of susceptible versus non-susceptible cell lines was performed, and comparison of membrane protein gene transcripts produced a list of 11 candidate receptors. Of these, only the human tumor cell marker PVRL4 (Nectin 4) rendered cells amenable to measles virus infections. Flow cytometry confirmed that PVRL4 is highly expressed on the surfaces of susceptible lung, breast, and colon adenocarcinoma cell lines. Measles virus preferentially infected adenocarcinoma cell lines from the apical surface, although basolateral infection was observed with reduced kinetics. Confocal immune fluorescence microscopy and surface biotinylation experiments revealed that PVRL4 was expressed on both the apical and basolateral surfaces of these cell lines. Antibodies and siRNA directed against PVRL4 were able to block measles virus infections in MCF7 and NCI-H358 cancer cells. A virus binding assay indicated that PVRL4 was a bona fide receptor that supported virus attachment to the host cell. Several strains of measles virus were also shown to use PVRL4 as a receptor. Measles virus infection reduced PVRL4 surface expression in MCF7 cells, a property that is characteristic of receptor-associated viral infections. Measles virus is a primate-specific virus that causes acute respiratory disease and can also lead to short term immune suppression resulting in secondary infections by bacteria or parasites. Wild type measles virus attaches to and infects lymphocytes using the receptor CD150 (signaling lymphocyte activation molecule, SLAM). Measles virus is also known to infect epithelial cells of the upper respiratory system and lungs. However, the viral receptor on these cells was previously unknown. Adenocarcinomas are derived from glandular epithelial cells of organs including the lung, breast, or colon. We showed that wild type isolates of measles virus can infect human airway epithelial cells and many adenocarcinoma cell lines. A comparative analysis of membrane genes expressed in cells susceptible and non-susceptible for measles virus infections revealed candidate receptor proteins. Only PVRL4 (Nectin 4) converted cells that were resistant to measles viral infections, to cells that could support virus infections. PVRL4 is a tumor cell marker that is highly expressed on embryonic cells such as those of the placenta, but it is also expressed at lower levels in the trachea, oral mucosa, nasopharynx, and lungs. It is highly expressed on many lung, breast, colon, and ovarian tumors suggesting that they could be targeted with oncolytic measles virus.

1 January 2014 in Journal of Traditional and Complementary Medicine
Verified
Journal Article
Open access
PDF file
LLLiang-Tzung Lin
Liang-Tzung Lin
WHWen-Chan Hsu
Wen-Chan Hsu
CLChun-Ching Lin
Chun-Ching Lin
Viral infections play an important role in human diseases, and recent outbreaks in the advent of globalization and ease of travel have underscored their prevention as a critical issue in safeguarding public health. Despite the progress made in immunization and drug development, many viruses lack preventive vaccines and efficient antiviral therapies, which are often beset by the generation of viral escape mutants. Thus, identifying novel antiviral drugs is of critical importance and natural products are an excellent source for such discoveries. In this mini-review, we summarize the antiviral effects reported for several natural products and herbal medicines.

4 January 2008 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
TWTzu-Hui Wu
Tzu-Hui Wu
FYFeng-Lin Yen
Feng-Lin Yen
LLLiang-Tzung Lin
Liang-Tzung Lin
TTTong-Rong Tsai
Tong-Rong Tsai
CLChun-Ching Lin
Chun-Ching Lin
TCThau-Ming Cham
Thau-Ming Cham

19 June 2015 in Carcinogenesis
Verified
Journal Article
Open access
PDF file
WGWilliam H. Goodson
William H. Goodson
LLLeroy Lowe
Leroy Lowe
DCDavid O. Carpenter
David O. Carpenter
MGMichael Gilbertson
Michael Gilbertson
AAAbdul Manaf Ali
Abdul Manaf Ali
Zhiwei HuZhiwei Hu
Zhiwei Hu
Lifestyle factors are responsible for a considerable portion of cancer incidence worldwide, but credible estimates from the World Health Organization and the International Agency for Research on Cancer (IARC) suggest that the fraction of cancers attributable to toxic environmental exposures is between 7% and 19%. To explore the hypothesis that low-dose exposures to mixtures of chemicals in the environment may be combining to contribute to environmental carcinogenesis, we reviewed 11 hallmark phenotypes of cancer, multiple priority target sites for disruption in each area and prototypical chemical disruptors for all targets, this included dose-response characterizations, evidence of low-dose effects and cross-hallmark effects for all targets and chemicals. In total, 85 examples of chemicals were reviewed for actions on key pathways/mechanisms related to carcinogenesis. Only 15% (13/85) were found to have evidence of a dose-response threshold, whereas 59% (50/85) exerted low-dose effects. No dose-response information was found for the remaining 26% (22/85). Our analysis suggests that the cumulative effects of individual (non-carcinogenic) chemicals acting on different pathways, and a variety of related systems, organs, tissues and cells could plausibly conspire to produce carcinogenic synergies. Additional basic research on carcinogenesis and research focused on low-dose effects of chemical mixtures needs to be rigorously pursued before the merits of this hypothesis can be further advanced. However, the structure of the World Health Organization International Programme on Chemical Safety ‘Mode of Action’ framework should be revisited as it has inherent weaknesses that are not fully aligned with our current understanding of cancer biology.

1 December 2015 in Seminars in Cancer Biology
Verified
Journal Article
Open access
KBKeith I. Block
Keith I. Block
CGCharlotte Gyllenhaal
Charlotte Gyllenhaal
LLLeroy Lowe
Leroy Lowe
Amedeo AmedeiAmedeo Amedei
Amedeo Amedei
AAA.R.M. Ruhul Amin
A.R.M. Ruhul Amin
FVFrancesca Valdora
Francesca Valdora
Targeted therapies and the consequent adoption of "personalized" oncology have achieved notable successes in some cancers; however, significant problems remain with this approach. Many targeted therapies are highly toxic, costs are extremely high, and most patients experience relapse after a few disease-free months. Relapses arise from genetic heterogeneity in tumors, which harbor therapy-resistant immortalized cells that have adopted alternate and compensatory pathways (i.e., pathways that are not reliant upon the same mechanisms as those which have been targeted). To address these limitations, an international task force of 180 scientists was assembled to explore the concept of a low-toxicity "broad-spectrum" therapeutic approach that could simultaneously target many key pathways and mechanisms. Using cancer hallmark phenotypes and the tumor microenvironment to account for the various aspects of relevant cancer biology, interdisciplinary teams reviewed each hallmark area and nominated a wide range of high-priority targets (74 in total) that could be modified to improve patient outcomes. For these targets, corresponding low-toxicity therapeutic approaches were then suggested, many of which were phytochemicals. Proposed actions on each target and all of the approaches were further reviewed for known effects on other hallmark areas and the tumor microenvironment. Potential contrary or procarcinogenic effects were found for 3.9% of the relationships between targets and hallmarks, and mixed evidence of complementary and contrary relationships was found for 7.1%. Approximately 67% of the relationships revealed potentially complementary effects, and the remainder had no known relationship. Among the approaches, 1.1% had contrary, 2.8% had mixed and 62.1% had complementary relationships. These results suggest that a broad-spectrum approach should be feasible from a safety standpoint. This novel approach has potential to be relatively inexpensive, it should help us address stages and types of cancer that lack conventional treatment, and it may reduce relapse risks. A proposed agenda for future research is offered.